Celltrion has struck a deal with Hong Kong’s Nan Fung Group to establish a local joint venture for developing and marketing biosimilars under the banner of Vcell Healthcare Limited.
Celltrion Sets Up JV With Nan Fung To Sell Biosimilars In China
Celltrion is pushing into biosimilar market opportunities in China by setting up a joint venture with local player Nan Fung Group. Vcell Healthcare is aiming to market three of Celltrion’s biosimilars as well as exploring setting up a manufacturing plant in China.
More from Deals
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.